An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies

[1]  L. Salassa,et al.  Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex , 2023, International journal of molecular sciences.

[2]  Yubin Huang,et al.  Iodine Conjugated Pt(IV) Nanoparticles for Precise Chemotherapy with Iodine-Pt Guided Computed Tomography Imaging and Biotin-Mediated Tumor-Targeting. , 2022, ACS nano.

[3]  I. Runnebaum,et al.  Synthesis and characterization of thiocarbonato-linked platinum(IV) complexes. , 2022, Dalton transactions.

[4]  Jialin Zhu,et al.  Nanoparticle delivery of a triple-action Pt(IV) prodrug to overcome cisplatin resistance via synergistic effect. , 2021, Biomaterials science.

[5]  A. Schintlmeister,et al.  Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo , 2021, Chemical science.

[6]  V. Brabec,et al.  Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? , 2021, Journal of medicinal chemistry.

[7]  P. Sadler,et al.  Facile protein conjugation of platinum for light-activated cytotoxic payload release , 2021, Chemical communications.

[8]  L. Antonuzzo,et al.  Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles , 2021, BioMetals.

[9]  N. Takeshima,et al.  Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis , 2020, BMC cancer.

[10]  E. Sobarzo-Sánchez,et al.  Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications , 2020, Molecules.

[11]  Peng Shi,et al.  Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light , 2019 .

[12]  Chungu Wang,et al.  Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance. , 2019, Bioorganic chemistry.

[13]  P. Sadler,et al.  New Designs for Phototherapeutic Transition Metal Complexes , 2019, Angewandte Chemie.

[14]  L. Massai,et al.  The cisplatin/serum albumin system: A reappraisal , 2019, Inorganica Chimica Acta.

[15]  F. Chiellini,et al.  Photocytotoxic Pt(iv) complexes as prospective anticancer agents. , 2019, Dalton transactions.

[16]  P. Sadler,et al.  Diazido platinum(iv) complexes for photoactivated anticancer chemotherapy , 2019, Inorganic Chemistry Frontiers.

[17]  Sumit Ghosh.  Cisplatin: The first metal based anticancer drug. , 2019, Bioorganic chemistry.

[18]  Hiroyuki Nakamura,et al.  Design of S-S bond containing maleimide-conjugated closo-dodecaborate (SSMID): identification of unique modification sites on albumin and investigation of intracellular uptake. , 2019, Organic & biomolecular chemistry.

[19]  I. Zanellato,et al.  Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen † , 2019, International journal of molecular sciences.

[20]  V. Brabec,et al.  A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton. , 2019, Journal of medicinal chemistry.

[21]  D. Gibson.  Multi-action Pt(IV) anticancer agents; do we understand how they work? , 2019, Journal of inorganic biochemistry.

[22]  C. Marmion,et al.  Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens? , 2019, Chemical reviews.

[23]  C. Pirker,et al.  Metal Drugs and the Anticancer Immune Response. , 2018, Chemical reviews.

[24]  Pedro M. P. Gois,et al.  Bioconjugation with Maleimides: A Useful Tool for Chemical Biology. , 2018, Chemistry.

[25]  K. Książek,et al.  Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells , 2018, Cellular and Molecular Life Sciences.

[26]  Hongqi Tian,et al.  Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands , 2018, Bioinorganic chemistry and applications.

[27]  A. Kumari,et al.  Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents , 2018, ACS omega.

[28]  Ri-zhen Huang,et al.  Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. , 2018, European journal of medicinal chemistry.

[29]  I. Zanellato,et al.  The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions. , 2018, Dalton transactions.

[30]  Ben Zhong Tang,et al.  Light-driven transformable optical agent with adaptive functions for boosting cancer surgery outcomes , 2018, Nature Communications.

[31]  Shi Jiao,et al.  A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors , 2018, Nature Communications.

[32]  Paul C. Wang,et al.  A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity. , 2018, Molecular pharmaceutics.

[33]  M. Galanski,et al.  The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study , 2018, Dalton transactions.

[34]  Ri-zhen Huang,et al.  Pt(IV) complexes conjugating with chalcone analogue as inhibitors of microtubule polymerization exhibited selective inhibition in human cancer cells. , 2018, European journal of medicinal chemistry.

[35]  I. Zanellato,et al.  An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate. , 2017, Dalton transactions.

[36]  E. Wang,et al.  Designing metal‐contained enzyme mimics for prodrug activation , 2017, Advanced drug delivery reviews.

[37]  Jinbiao Zhan,et al.  Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates , 2017, Drug design, development and therapy.

[38]  N. Margiotta,et al.  Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug , 2017 .

[39]  V. Brabec,et al.  Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates , 2017, Scientific Reports.

[40]  C. Thompson,et al.  Nutrient acquisition strategies of mammalian cells , 2017, Nature.

[41]  Weiqiang Huang,et al.  Folic Acid-Conjugated Pyropheophorbide a as the Photosensitizer Tested for In Vivo Targeted Photodynamic Therapy. , 2017, Journal of pharmaceutical sciences.

[42]  A. Najjar,et al.  Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy. , 2017, Current pharmaceutical design.

[43]  I. Zanellato,et al.  May glutamine addiction drive the delivery of antitumor cisplatin-based Pt(IV) prodrugs? , 2017, Journal of inorganic biochemistry.

[44]  I. Zanellato,et al.  Cisplatin and valproate released from the bifunctional [Pt(IV)Cl2(NH3)2(valproato)2] antitumor prodrug or from liposome formulations: who does what? , 2017, Dalton transactions.

[45]  Seok Hyun Yun,et al.  Light in diagnosis, therapy and surgery , 2016, Nature Biomedical Engineering.

[46]  R. Weichselbaum,et al.  Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.

[47]  J. Sessler,et al.  Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. , 2016, Angewandte Chemie.

[48]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[49]  D. Gibson.  Platinum(iv) anticancer prodrugs - hypotheses and facts. , 2016, Dalton transactions.

[50]  Ri-zhen Huang,et al.  Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action. , 2016, Bioconjugate chemistry.

[51]  V. Brabec,et al.  Activation of Platinum(IV) Prodrugs by Cytochrome c and Characterization of the Protein Binding Sites. , 2016, Molecular pharmaceutics.

[52]  Jun Chen,et al.  Tumor-Homing and Penetrating Peptide-Functionalized Photosensitizer-Conjugated PEG-PLA Nanoparticles for Chemo-Photodynamic Combination Therapy of Drug-Resistant Cancer. , 2016, ACS applied materials & interfaces.

[53]  J. Coward,et al.  Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. , 2016, Critical reviews in oncology/hematology.

[54]  Jinhui Hu,et al.  Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo. , 2016, Journal of medicinal chemistry.

[55]  S. Gou,et al.  Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes. , 2016, European journal of medicinal chemistry.

[56]  Kondo‐François Aguey‐Zinsou,et al.  Selective Photoactivation: From a Single Unit Monomer Insertion Reaction to Controlled Polymer Architectures. , 2016, Journal of the American Chemical Society.

[57]  S. Lippard,et al.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. , 2016, Chemical reviews.

[58]  V. Brabec,et al.  Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c5sc04205d , 2016, Chemical science.

[59]  Jin Sun,et al.  Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy , 2015, Medicinal research reviews.

[60]  Jinhui Hu,et al.  Synthesis, biological evaluation and mechanism study of chalcone analogues as novel anti-cancer agents , 2015 .

[61]  V. Brabec,et al.  New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells. , 2015, Biochemical pharmacology.

[62]  S. Gou,et al.  Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane. , 2015, European journal of medicinal chemistry.

[63]  C. Patrono,et al.  Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. , 2015, Biochimica et biophysica acta.

[64]  V. Fokin,et al.  Synthesis and biological evaluation of furanoallocolchicinoids. , 2015, Journal of medicinal chemistry.

[65]  L. Marnett,et al.  Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance , 2015, ChemMedChem.

[66]  Jiangtao Xu,et al.  Utilizing the electron transfer mechanism of chlorophyll a under light for controlled radical polymerization , 2014, Chemical science.

[67]  Gurneet Kaur,et al.  Recent developments in tubulin polymerization inhibitors: An overview. , 2014, European journal of medicinal chemistry.

[68]  V. Brabec,et al.  Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands. , 2014, Journal of inorganic biochemistry.

[69]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[70]  A. Florea,et al.  Cisplatin (CDDP) triggers cell death of MCF-7 cells following disruption of intracellular calcium ([Ca(2+)]i) homeostasis. , 2014, The Journal of toxicological sciences.

[71]  Mingli Xiang,et al.  Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors. , 2014, Journal of medicinal chemistry.

[72]  D. Richardson,et al.  Unraveling the mysteries of serum albumin—more than just a serum protein , 2014, Front. Physiol..

[73]  S. Bhattacharyya,et al.  A novel naproxen derivative capable of displaying anti-cancer and anti-migratory properties against human breast cancer cells , 2014, BMC Cancer.

[74]  Hong Wang,et al.  The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells. , 2014, Chemical communications.

[75]  Abhigna Polavarapu,et al.  Understanding intrinsically irreversible, non-Nernstian, two-electron redox processes: a combined experimental and computational study of the electrochemical activation of platinum(IV) antitumor prodrugs. , 2014, Journal of the American Chemical Society.

[76]  L. Marnett,et al.  Conjugates of Cisplatin and Cyclooxygenase Inhibitors as Potent Antitumor Agents Overcoming Cisplatin Resistance , 2014, ChemMedChem.

[77]  Michael R Hamblin,et al.  Physical energy for drug delivery; poration, concentration and activation. , 2014, Advanced drug delivery reviews.

[78]  S. Baek,et al.  Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. , 2014, Cancer letters.

[79]  Yuquan Wei,et al.  Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents. , 2014, Bioorganic & medicinal chemistry.

[80]  Magnar Bjørås,et al.  Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding* , 2014, The Journal of Biological Chemistry.

[81]  S. Dhar,et al.  The prodrug platin-A: simultaneous release of cisplatin and aspirin. , 2014, Angewandte Chemie.

[82]  S. Lippard,et al.  Conjugation of vitamin E analog α-TOS to Pt(IV) complexes for dual-targeting anticancer therapy. , 2013, Chemical communications.

[83]  W. Bal,et al.  Binding of transition metal ions to albumin: sites, affinities and rates. , 2013, Biochimica et biophysica acta.

[84]  J. Fajkus,et al.  New perspectives of valproic acid in clinical practice , 2013, Expert opinion on investigational drugs.

[85]  V. Ahsen,et al.  Assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties. , 2013, Molecular pharmaceutics.

[86]  S. Lippard,et al.  Synthesis and characterization of Pt(IV) fluorescein conjugates to investigate Pt(IV) intracellular transformations. , 2013, Bioconjugate chemistry.

[87]  Justin J. Wilson,et al.  Monofunctional and higher-valent platinum anticancer agents. , 2013, Inorganic chemistry.

[88]  C. Twelves,et al.  Tubulin: an example of targeted chemotherapy. , 2013, Future medicinal chemistry.

[89]  W. Berger,et al.  Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. , 2013, Chemical communications.

[90]  T. Hambley,et al.  Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design. , 2013, Chemistry.

[91]  Frank Jensen,et al.  Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes , 2012, Journal of medicinal chemistry.

[92]  E. Wexselblatt,et al.  What do we know about the reduction of Pt(IV) pro-drugs? , 2012, Journal of inorganic biochemistry.

[93]  M. Jakupec,et al.  Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. , 2012, Dalton transactions.

[94]  N. Margiotta,et al.  Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs. , 2012, Dalton transactions.

[95]  María Kimatrai Salvador,et al.  Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents. , 2012, Journal of medicinal chemistry.

[96]  D. Xing,et al.  Pyropheophorbide A and c(RGDyK) comodified chitosan-wrapped upconversion nanoparticle for targeted near-infrared photodynamic therapy. , 2012, Molecular pharmaceutics.

[97]  W. Berger,et al.  Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs , 2012, Molecular Pharmacology.

[98]  Justin J. Wilson,et al.  In vitro anticancer activity of cis-diammineplatinum(II) complexes with β-diketonate leaving group ligands. , 2012, Journal of medicinal chemistry.

[99]  L. Galluzzi,et al.  Molecular mechanisms of cisplatin resistance , 2012, Oncogene.

[100]  D. Kerwood,et al.  Pt(IV) complexes as prodrugs for cisplatin. , 2012, Journal of inorganic biochemistry.

[101]  T. Hambley,et al.  Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. , 2012, Chemical communications.

[102]  P. Hergenrother,et al.  Whole cell microtubule analysis by flow cytometry. , 2012, Analytical biochemistry.

[103]  M. Sliwkowski,et al.  Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.

[104]  N. Eckstein,et al.  Platinum resistance in breast and ovarian cancer cell lines , 2011, Journal of experimental & clinical cancer research : CR.

[105]  W. Berger,et al.  Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.

[106]  E. Frei.  Albumin binding ligands and albumin conjugate uptake by cancer cells , 2011, Diabetology & metabolic syndrome.

[107]  Richard A. Stanton,et al.  Drugs that target dynamic microtubules: A new molecular perspective , 2011, Medicinal research reviews.

[108]  Justin J. Wilson,et al.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes. , 2011, Inorganic chemistry.

[109]  K. Geissler,et al.  Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells , 2011, Journal of experimental pharmacology.

[110]  Dietrich Büsselberg,et al.  Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects , 2011, Cancers.

[111]  Manivannan Ethirajan,et al.  The role of porphyrin chemistry in tumor imaging and photodynamic therapy. , 2011, Chemical Society reviews.

[112]  V. Brabec,et al.  Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione. , 2010, Molecular pharmaceutics.

[113]  Shonagh Walker,et al.  The status of platinum anticancer drugs in the clinic and in clinical trials. , 2010, Dalton transactions.

[114]  K. Tew,et al.  Redox metabolism and malignancy. , 2010, Current opinion in pharmacology.

[115]  M. Lion,et al.  Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro , 2010, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[116]  Eva Frei,et al.  Native albumin for targeted drug delivery , 2010, Expert opinion on drug delivery.

[117]  H. Harada,et al.  Synthesis and biological evaluation of indolyl chalcones as antitumor agents. , 2010, Bioorganic & medicinal chemistry letters.

[118]  K. B. Garbutcheon-Singh,et al.  Advances in platinum chemotherapeutics. , 2010, Chemistry.

[119]  G. Hamilton,et al.  A better platinum-based anticancer drug yet to come? , 2010, Anti-cancer agents in medicinal chemistry.

[120]  K. Takrouri,et al.  New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs. , 2010, Chemical communications.

[121]  M. Kavallaris.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[122]  S. Lippard,et al.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate , 2009, Proceedings of the National Academy of Sciences.

[123]  N. Lawrence,et al.  Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. , 2009, Bioorganic & medicinal chemistry.

[124]  William Berry,et al.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  U. Vaishampayan,et al.  Satraplatin: leading the new generation of oral platinum agents , 2009, Expert opinion on investigational drugs.

[126]  Seong-ho Lee,et al.  A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. , 2009, Cancer letters.

[127]  T. Mueller,et al.  Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. , 2009, Journal of medicinal chemistry.

[128]  Felix Kratz,et al.  Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[129]  Z. Dong,et al.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. , 2008, Kidney international.

[130]  H. Choy,et al.  Current Status and Future Prospects for Satraplatin, an Oral Platinum Analogue , 2008, Clinical Cancer Research.

[131]  W. Berger,et al.  Resistance against novel anticancer metal compounds: differences and similarities. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[132]  D. Gibson,et al.  Reduction of cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by aqueous extracts of cancer cells. , 2007, Journal of medicinal chemistry.

[133]  Stefan Trapp,et al.  Mitochondriotropics: a review of their mode of action, and their applications for drug and DNA delivery to mammalian mitochondria. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[134]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[135]  M. Hall,et al.  Basis for design and development of platinum(IV) anticancer complexes. , 2007, Journal of medicinal chemistry.

[136]  Xiu-fang Wang,et al.  Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II , 2007, Journal of bioenergetics and biomembranes.

[137]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[138]  S. Baek,et al.  NSAID activated gene (NAG-1), a modulator of tumorigenesis. , 2006, Journal of biochemistry and molecular biology.

[139]  Xiu-fang Wang,et al.  Molecular mechanism of ‘mitocan’‐induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl‐2 family proteins , 2006, FEBS letters.

[140]  L. Galluzzi,et al.  Mitochondria as therapeutic targets for cancer chemotherapy , 2006, Oncogene.

[141]  P. Leder,et al.  Mitochondriotoxic compounds for cancer therapy , 2006, Oncogene.

[142]  J. Martinou,et al.  Mitochondria and cancer: is there a morphological connection? , 2006, Oncogene.

[143]  H. Choy.  Satraplatin: an orally available platinum analog for the treatment of cancer , 2006, Expert review of anticancer therapy.

[144]  K. Watabe,et al.  Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis , 2006, International journal of cancer.

[145]  Dasheng Wang,et al.  α-Tocopheryl Succinate Induces Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Function* , 2006, Journal of Biological Chemistry.

[146]  Giovanni Sorba,et al.  Medicinal chemistry of combretastatin A4: present and future directions. , 2006, Journal of medicinal chemistry.

[147]  J. Zweier,et al.  Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[148]  D. Green,et al.  Mitochondria, apoptosis and autoimmunity. , 2006, Current directions in autoimmunity.

[149]  M. McKeage,et al.  Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro , 2006, Cancer Chemotherapy and Pharmacology.

[150]  M. Jakupec,et al.  Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. , 2005, Current medicinal chemistry.

[151]  P Jack Hoopes,et al.  Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. , 2005, Cancer research.

[152]  M. Steinmetz,et al.  Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.

[153]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[154]  S. Loi,et al.  Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial , 2005, British Journal of Cancer.

[155]  B. Keppler,et al.  Analysis of anticancer platinum(II)‐complexes by microemulsion electrokinetic chromatography: Separation of diastereomers and estimation of octanol‐water partition coefficients , 2005, Electrophoresis.

[156]  Seong-ho Lee,et al.  Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein , 2005, Molecular Pharmacology.

[157]  Xiu-fang Wang,et al.  Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. , 2005, Biochemical and biophysical research communications.

[158]  D. Budman,et al.  Review: Tubulin Function, Action of Antitubulin Drugs, and New Drug Development , 2005, Cancer investigation.

[159]  J. Quin,et al.  Vitamin E succinate decreases lung cancer tumor growth in mice. , 2004, The Journal of surgical research.

[160]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[161]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[162]  S. Papa,et al.  Reactive oxygen species, mitochondria, apoptosis and aging , 2004, Molecular and Cellular Biochemistry.

[163]  I. Smith,et al.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II , 2004, Cancer Chemotherapy and Pharmacology.

[164]  J. Neuzil,et al.  Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity , 2003, British Journal of Cancer.

[165]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[166]  S. Baek,et al.  Nonsteroidal anti‐inflammatory drug‐activated gene (NAG‐1) is induced by genistein through the expression of p53 in colorectal cancer cells , 2003, International journal of cancer.

[167]  K. Iczkowski,et al.  Overexpression of NSAID-Activated Gene Product in Prostate Cancer , 2003, International journal of surgical pathology.

[168]  B. G. Sanders,et al.  RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells involves Bax translocation to mitochondria. , 2003, Cancer research.

[169]  A. Nègre-Salvayre,et al.  Mitochondria play a central role in apoptosis induced by alpha-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. , 2003, Biochemistry.

[170]  D. Newmeyer,et al.  Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.

[171]  J. Perez,et al.  Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. , 2003, Current medicinal chemistry.

[172]  T W Evans,et al.  Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure , 2002, Alimentary pharmacology & therapeutics.

[173]  M. Hall,et al.  Platinum(IV) antitumour compounds: their bioinorganic chemistry , 2002 .

[174]  S. Baek,et al.  Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. , 2002, The Journal of pharmacology and experimental therapeutics.

[175]  M. McKeage,et al.  Rapid biotransformation of satraplatin by human red blood cells in vitro , 2002, Cancer Chemotherapy and Pharmacology.

[176]  J. Arezzo,et al.  Salicylate Protects Hearing and Kidney Function from Cisplatin Toxicity without Compromising its Oncolytic Action , 2002, Laboratory Investigation.

[177]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[178]  E. Nogales,et al.  Refined structure of alpha beta-tubulin at 3.5 A resolution. , 2001, Journal of molecular biology.

[179]  K. Hattori,et al.  Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. , 2001, Biological & pharmaceutical bulletin.

[180]  S. Baek,et al.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. , 2001, Molecular pharmacology.

[181]  S. Minoura,et al.  Indomethacin increases the cytotoxicity of cis-platinum and 5-fluorouracil in the human uterine cervical cancer cell lines SKG-2 and HKUS by increasing the intracellular uptake of the agents , 2001, International Journal of Clinical Oncology.

[182]  W. Kiefer,et al.  Cyclooxygenase inhibitors--current status and future prospects. , 2001, European journal of medicinal chemistry.

[183]  J. Platts,et al.  Calculation of the hydrophobicity of platinum drugs. , 2001, Journal of medicinal chemistry.

[184]  J. Neuzil,et al.  Selective cancer cell killing by α-tocopheryl succinate , 2001, British Journal of Cancer.

[185]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[186]  M. Malafa,et al.  Vitamin E succinate promotes breast cancer tumor dormancy. , 2000, The Journal of surgical research.

[187]  A. Stocker,et al.  Vitamin E: non-antioxidant roles. , 2000, Progress in lipid research.

[188]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[189]  T. Kuczek,et al.  Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer , 2000, Cancer Chemotherapy and Pharmacology.

[190]  E. Giovannucci.  The prevention of colorectal cancer by aspirin use. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[191]  J. Neuzil,et al.  α‐Tocopheryl succinate‐induced apoptosis in Jurkat T cells involves caspase‐3 activation, and both lysosomal and mitochondrial destabilisation , 1999, FEBS letters.

[192]  Seymour,et al.  Control of tumour vascular permeability. , 1998, Advanced drug delivery reviews.

[193]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[194]  M. Clynes,et al.  Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). , 1998, European journal of cancer.

[195]  J Christodoulou,et al.  Cisplatin Binding Sites on Human Albumin* , 1998, The Journal of Biological Chemistry.

[196]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[197]  A. Ristimäki,et al.  Expression of cyclooxygenase-2 in human gastric carcinoma. , 1997, Cancer research.

[198]  D. Riendeau,et al.  Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. , 1996, Gastroenterology.

[199]  A. Vogler,et al.  Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. , 1996, Anti-cancer drug design.

[200]  G Siest,et al.  Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. , 1995, Clinical chemistry.

[201]  T. Hambley,et al.  The Influence of the Axial Ligands of a Series of Platinum(IV) Anti-Cancer Complexes on Their Reduction to Platinum(II) and Reaction With DNA , 1995 .

[202]  D. Dewitt,et al.  Expression of the murine prostaglandin (PGH) synthase-1 and PGH synthase-2 isozymes in cos-1 cells. , 1993, Journal of lipid mediators.

[203]  D. Rotrosen,et al.  Ascorbic acid in human neutrophils. , 1991, The American journal of clinical nutrition.

[204]  W. Gispen,et al.  Neurotoxic side-effects of cisplatin. , 1991, European journal of cancer.

[205]  S. Wyrick,et al.  In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma. , 1990, Cancer research.

[206]  M. L. Edwards,et al.  Chalcones: a new class of antimitotic agents. , 1990, Journal of medicinal chemistry.

[207]  M. Traber,et al.  Vitamin E: antioxidant activity, biokinetics, and bioavailability. , 1990, Annual review of nutrition.

[208]  E. Hamel,et al.  Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. , 1989, Biochemistry.

[209]  A. McGown,et al.  Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. , 1989, Anti-cancer drug design.

[210]  J. Cowens,et al.  Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans. , 1988, Cancer research.

[211]  K. Kimura,et al.  Clinical Pharmacokinetics of Carboplatin , 1988, Journal of clinical pharmacology.

[212]  V. Peyrot,et al.  In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II). , 1986, Biochemical pharmacology.

[213]  A. Peters,et al.  Reaction products from platinum(IV) amine compounds and 5'-GMP are mainly bis(5'-GMP)platinum(II) amine adducts. , 1986, Journal of inorganic biochemistry.

[214]  K. Kaga,et al.  Cisplatin , 1982, The Lancet.

[215]  U Kragh-Hansen,et al.  Molecular aspects of ligand binding to serum albumin. , 1981, Pharmacological reviews.

[216]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[217]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.